Michael Boeckh, Helen Y. Chu,Janet A. Englund, Christina M. Lockwood, Deborah A. Nickerson, Jay Shendure and Lea Starita
Wrote:
"Our efforts to test for SARS-CoV-2 in the community were constrained by the labyrinth of conflicting and uncoordinated actions among state and federal regulators"
https://www.nature.com/articles/s41591-021-01587-0.pdf
The labyrinth has given rise to a number of conflicting and uncoordinated descriptions of the constraining actions, some of which aren't exactly true.
In my opinion, the two most widely reported and widely misreported constraints were:
(1) The "Seattle Flu Study" was initially unprepared to release individual results, because that was not what they had approval for from the studied individuals.
(2) The USFDA (US Food and Drug Administration) required emergency use authorization (EUA) for any test that would return results.
Those two constraints, at different times, prevented the Seattle Flue Study from contacting infected individuals and those providing medical care to infected individuals.
Neither of these two important constraints prevented the Seattle Flu Study from running tests on flu swabs, publishing data from those tests, or even speaking to the media about those tests.
Individuals within the SFS may well feel that they had been gagged by their institution or their regulators: I would be surprised if that was not the case. But the general effect complained about was not the suppression of publicity: it was about the failure to find a way for effective medical/health use of the information.